Pharmacogenetic applications of the human genome project

Nature Medicine

Volumn 7, Issue 3, 2001, Pages 281-283

  Liggett, S B ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT;

ASTHMA; CLINICAL RESEARCH; DRUG EFFECT; DRUG RESPONSE; ETHNIC GROUP; GENE MAPPING; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MEDICAL GENETICS; PHARMACOGENETICS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM;

DRUG THERAPY; HUMAN GENOME PROJECT; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 0035105777     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/85411     Document Type: Short Survey

References (10)

1. Initial sequencing and analysis of the human genome
2. A map of human genome sequence variation containing 1.4 million single nucleotide polymorphisms
3. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: A randomized, control trial
4. Heterogeneity of therapeutic responses in asthma
5. Apolipoprotein E variation at the sequence haplotype level: Implications for the origin and maintenance of a major human polymorphism
6. 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness
7. 2c-adrenergic receptor confers impaired coupling to multiple effectors
8. The predictive power of haplotypes in clinical response
9. Association of β(2)-adrenoreceptor variants with bronchial hyperresponsiveness
10. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment